On October 27, BRAINAURORA-B recorded an Intraday Rise of 22.87% in Regular Trading, reaching HK$1.155, with turnover of HK$390 million.
The move coincided with renewed market attention on the company’s previously disclosed expectation that its depression cognitive function assessment product may obtain a registration certificate in November, alongside fresh interest in advances in brain-computer interface standards.
Background disclosures showed gross profit of about RMB54.61 million, up 33.68%, while gross margin improved from 40.8% to 45.6%. Period loss was about RMB135 million, and adjusted net loss was about RMB99.19 million. Management also said its core products have been included in provincial medical insurance reimbursement catalogues across 30 provinces, while its reading disorder-assisted rehabilitation training product is expected to complete clinical research in December.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments